Published on: 2026-09-09
Updated on: 2026-09-09
Holtec Nuclear is offering 50 million Class A shares at $15 to $18 each under the proposed ticker HNUC, implying an equity valuation of roughly $8.5 billion to $10.2 billion. The valuation spans an established nuclear-services business, the unfinished Palisades restart and SMR-300, which remains in pre-deployment.
The IPO case rests less on Holtec’s eye-catching 2025 net income than on the restructured public company's recurring earnings and how quickly Palisades and future reactor projects can begin contributing cash flow.
| IPO detail | Current position |
|---|---|
| Proposed ticker | HNUC |
| Price range | $15 to $18 |
| Shares offered | 50 million |
| Gross proceeds | $750 million to $900 million |
| Implied equity value | About $8.5 billion to $10.2 billion |
| Midpoint valuation | About $9.35 billion |
| Exchange | Nasdaq Global Select Market and Nasdaq Texas |
| Expected trading date | September 18, 2026, provisional |
| Final offer price | Not yet set |
| Official trading date | Not yet confirmed |
On the prospectus’s 566.7 million as-exchanged share count, the proposed range implies about $8.5 billion of equity value at $15, $9.35 billion at the $16.50 midpoint and $10.2 billion at $18.
September 18, 2026 is the current expected trading date, although Holtec has not confirmed it in the prospectus.
Webull currently lists September 17 as the offering end date and September 18 as the expected listing date, while IPO Scoop also places HNUC’s expected debut on September 18. Holtec’s September 8 SEC filing still leaves the final pricing and share-delivery dates blank, so the timetable remains provisional.
Holtec’s proposed valuation looks more demanding when measured against the earnings attributable to the public company after the reorganisation.
The prospectus reports 2025 pro forma Class A earnings per share of $0.40. The proposed range therefore values HNUC at 37.5 times pro forma earnings at $15, about 41.3 times at the $16.50 midpoint and 45 times at $18.
| Offer price | Equity value | Pro forma P/E |
|---|---|---|
| $15.00 | $8.50bn | 37.5x |
| $16.50 | $9.35bn | 41.3x |
| $18.00 | $10.20bn | 45.0x |
A 37.5x to 45.0x multiple leaves the valuation dependent on growth beyond the current earnings base. Palisades, manufacturing expansion and SMR-300 all carry economic weight in a price range well above what Holtec’s present recurring earnings alone would imply.
The valuation therefore embeds substantial value in businesses and projects that are either still ramping or have yet to reach commercial operation.
Holtec International reported $576.6 million of 2025 revenue and $386.6 million of net income, while operating income was only $37.1 million.
Net other income reached approximately $433.9 million, driven heavily by realized and unrealized investment gains associated with nuclear decommissioning trusts. Those gains created a large gap between operating performance and headline profit.
The restructuring moves several decommissioning businesses and their trust assets outside the listed group.
Consequently, the prospectus presents a different post-transaction earnings profile. On a 2025 pro forma basis, revenue rises to $893.4 million, operating income reaches $140.2 million, and net income falls to $217.0 million.
The higher revenue reflects a change in consolidation rather than a sudden increase in underlying activity. Services previously performed between companies inside Holtec can become external revenue once the decommissioning entities sit outside HNUC, while much of their investment income leaves the consolidated earnings base.
Historical net profit is therefore a poor standalone measure of the recurring earnings power entering the IPO.
After the reorganisation, HNUC will retain Holtec’s nuclear products and services operations, the Palisades nuclear plant, and the SMR-300 program.
Pilgrim, Indian Point, Oyster Creek and Big Rock Point are being placed within the separately controlled DEAMCO structure, subject to regulatory approvals still required to complete the restructuring. Holtec expects to continue providing decommissioning services to those entities under contractual arrangements.
The resulting public company combines an established nuclear-services business, Palisades as its nearest major operating catalyst and SMR-300 as its longest-duration growth asset.
Public Class A shares are expected to represent about 8.8% of common-stock ownership on an as-exchanged basis, but only about 1% of the voting power for director elections. Founder-affiliated interests are expected to retain approximately 99%.
Holtec Holdings and entities controlled by founder and chief executive Krishna Singh hold Class B shares with 10 votes each, compared with one vote per Class A share. Holtec will therefore qualify as a controlled company under Nasdaq listing standards.
The structure also includes a tax receivable agreement under which Holtec Nuclear will generally pay founder-linked beneficiaries 85% of certain realized cash tax savings created by tax attributes arising from the reorganisation.
Using the $16.50 midpoint and assumptions covering future taxable income and tax law, Holtec estimates the present value of payments arising from the reorganisation and IPO at approximately $1.6 billion.
The prospectus also estimates an approximately $2.6 billion payment under an assumed immediate termination of the agreement. That amount is not due when HNUC lists. It represents the potential scale of the obligation under a specific acceleration scenario.
Palisades offers Holtec a clearer route to recurring power revenue than SMR-300.
Holtec began loading nuclear fuel into the approximately 800 MW Michigan reactor on August 30. The September 8 NRC reactor status report still showed Palisades at 0% power, so fuel loading has not yet translated into commercial electricity generation.
The plant’s output is covered by power purchase agreements with Wolverine Power Cooperative and Hoosier Energy. Both agreements carry initial 28-year terms and provide fixed-price electricity sales subject to contractual adjustments.
Holtec spent approximately $639.4 million on the Palisades segment in the first half of 2026, while the Department of Energy loan guarantee supports Federal Financing Bank advances of up to $1.52 billion.
A successful restart would move Palisades from a major capital consumer toward a contracted generating asset.
Holtec’s SMR-300 program represents the longest-duration part of the IPO growth case.
The proposed Pioneer project at Palisades would include two SMR-300 units with 680 MWe of combined capacity, with commercial operation targeted for the early 2030s, subject to financing, licensing, and construction progress.
Holtec’s SMR-300 program sits in the development-stage segment of the broader nuclear stock boom, where valuations can move well ahead of operating reactor economics.
Management targets gross margins of 25% to 35% under its commercialization model. These are company targets, not historical operating margins.
Any valuation contribution from SMR-300 therefore rests on future regulatory approvals, financing, construction and commercial execution rather than current operating cash flow.
No. Holtec has launched the IPO roadshow and applied to list Class A shares under HNUC, but the offering had not been finally priced as of September 9, 2026. The prospectus also does not yet contain a confirmed first trading date.
No. The approximately $10.2 billion figure assumes an $18 IPO price and 566.7 million shares on an as-exchanged basis. The proposed range implies about $8.5 billion at $15 and $9.35 billion at the $16.50 midpoint.
No. HNUC will retain Holtec’s nuclear products and services operations, Palisades and SMR-300, while Pilgrim, Indian Point, Oyster Creek and Big Rock Point are being moved into the separately controlled DEAMCO structure.
About 1% of the voting power for director elections. Founder-affiliated entities are expected to retain roughly 99% after the IPO, even though public Class A shares represent about 8.8% of common-stock ownership on an as-exchanged basis.
Final pricing will establish HNUC’s opening valuation before Palisades begins commercial generation. The restart is then the most immediate operating test, with successful commercial operation adding contracted power revenue alongside Holtec’s existing nuclear-services business.
Beyond Palisades, SMR-300 licensing, financing and binding commercial agreements will determine how much of the longer-term growth case moves from projected economics into measurable revenue and cash flow.
